Navigation Links
CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS

ng 400 mg of arimoclomol three times daily for 28 days. The results of this safety study will be reported early in the fourth quarter of this year, prior to the planned initiation of the Phase IIb efficacy trial.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to FDA clearance. The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS and has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.

About RXi Pharmaceuticals Corporation

Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early pate
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:
(Date:11/25/2009)...Call/--Hologic,Inc.(HologicortheCompany)(Nasdaq: H...remiumdiagnostics,medicalimagingsystemsandsurgical...n,isusingtheannualmeetingoftheRadiologicalSocietyo...ber29throughDecember3,2009tohighlightournewSecurVi...stationsoftware. ,, TheHologicSecurViewworkstat...
(Date:11/25/2009)...dsResearchGroup,Inc.releasedWave1ofits LaunchTren...yndicatedmarketresearchprojecttrackingthelaunchofC...oughthefirstsixmonthsofavailability.Eachwaveofther...rmatologistsandqualitativeinformationfromasubsetof...ouse,typicalpatienttypes,productperceptions,promot...
(Date:11/25/2009)...e/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAmeric...hatitreceivedtheEnvironmentalResponsibilityandSust...mmit,sponsoredbytheCaliforniaManufacturersandTechn...ssociation(IEA)andtheChemicalIndustryCouncilofCali...sawardavailablefromallthreeorganizationsandgainssu...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 1AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 3AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 4AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 5AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 6AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 7AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 8AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 9AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 10AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 11AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 12AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 13AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 14AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 15AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 16AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 17AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 18AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 1AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 2AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 3First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 1First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 2First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 3
...reported in,the journal Pharmacogenomics suggests ...ic Factor gene (CNTF) may affect response to,antip...Pharmaceuticals,Inc., included patients with acute... with Fiapta(TM) (iloperidone), a novel atypical,a... FDA, or placebo.,Patients were also studied for a...
...r Blood-Derived Stem Cells and Strong In...NEW YORK, Feb. 28 NeoStem, Inc. (Amex: NBS ),whi...ssing and long-term,storage of adult stem cells fo...ositive research conclusions and industry trends p...sociation and at the recent Third Annual,Stem Cell...
Other Medicine Technology:Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 2NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 4
(Date:11/25/2009)..., SILVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--...nterforDrugEvaluationandResearch,titled"ADifficult...rsintheNov.26,2009issueofTheNewEnglandJournalofMed.../prnh/20090824/FDALOGO ) ,, Inthearticle,Woodco...topainmedicationforthosewhoneeditandmanagingtheris...
(Date:11/25/2009)..., SANFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQu...inter Spare the Air Alert forThursda...firelogsoranyothersolidfuel,bothindoorsandoutdoors...yairqualitytomorrow,"saidJackBroadbent,executiveof...torespectthehealthoftheirneighborsandfellowcommuni...
(Date:11/25/2009)...-term survivors of testicular cancer who were trea...ere side effects, including neurological side effe...not treated with chemotherapy, according to a new ... of the National Cancer Institute . , Marianne B...nd University Hospital, in Bergen, Norway, and col...
(Date:11/25/2009)...fortuitous discovery that grew out of a collaborat...tentially offer hope to the nearly 10 million Amer... , Also known as hardening of the arteries, ...irculatory problem in which narrowed arteries redu...dered a red flag for vascular disease, heart attac...
(Date:11/25/2009)...udy follow-up period was too short to draw definit...AY, Nov. 25 (HealthDay News) -- In diabetic patien...o be no difference in outcomes at one year whether...th stenting, British researchers report. , Bypa...betic patients with coronary artery disease. Howev...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
...norrhea, one of the most common sexually transmitt...scientists say they are running // out of options ...ibe a group of commonly used antibiotics including...ion (CDC) says that the sexual disorder-that affec...
...rmaphrodites, commonly known as eunuchs, can now c...ive birth to babies - thanks //to a special proced...l Sciences (AIIMS) here. After proper diagnos...ier research and referral institute said. "T...
...Child abuse casts a shadow the length of a lifetim...tter Truth Little Sana was home alone, happ...while her mom eked out a living in a neighborhood .... He locked the door and raped her repeatedly. ...
...th allergy season in full bloom, the American Acad...ffering a reminder of what you can do to cope with...throat specialist can help. // This spring, p...s, nasal congestion and drainage, and sometimes he...
...ti-smoking campaigns highlighting the risk of resp... at women, according to a new study published in t...rofessor Robert Adams of the Queen Elizabeth Hospi...found hospital admissions and mortality from asthm...
...ctors should not shy away from writing letters of ... according to an article in the latest Medical Jou...igious society, some doctors may be wary of pennin... 'Letters can be dangerous in the hands of law...
Other Medicine News:Health News:Scientists Concerned About Gonorrhea’s Drug Resistanc 2Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2
Frazier
Ferguson-Frazier suction tube # 4
Ferguson-Frazier suction tube # 0
UltraLite® Plus Headlight System
Medicine Products: